Nucleoside analogs are synthetic molecules designed to look like the natural building blocks of DNA and RNA but with small chemical tweaks that let them sabotage the copying machinery of viruses or cancer cells. They rank among the most widely used drug classes in medicine, forming the backbone of treatments for HIV, hepatitis B and C, herpes viruses, and several cancers. The concept is deceptively simple: slip a counterfeit piece into the assembly line and watch it jam. But how each analog pulls off that trick, why some target viruses while others target tumors, and what makes them occasionally harmful to healthy cells are all worth understanding in more detail.
The Disguise
Your cells build DNA and RNA from four natural nucleosides, each made of a sugar attached to one of the bases that encode genetic information. Nucleoside analogs mirror this structure closely enough to fool the enzymes responsible for copying genetic material, but they carry chemical modifications that interfere with the copying process once they get incorporated.1Journal of Chemical Information and Modeling. NA-DB: An Online Database of Nucleoside Analogues Some analogs have their sugar ring altered. Others have the base itself reshaped. The earliest modifications, dating back to the 1960s, involved swapping the natural ribose sugar for an arabinose sugar, producing a family of drugs that are still used in cancer treatment today.2PubMed Central. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
The critical thing about these modifications is that they are subtle. If an analog looked nothing like a natural nucleoside, the cell’s enzymes would reject it outright. The art of drug design here is making something just similar enough to be accepted but just different enough to cause problems once it is in place.
Getting Switched On Inside the Cell
A nucleoside analog does not arrive in the cell ready to fight. It enters as a prodrug, an inactive form that the cell must activate through a series of chemical reactions. Specifically, the cell’s own enzymes attach phosphate groups to it in three successive steps, converting the analog into its active triphosphate form.3PubMed Central. Lipophilic Nucleoside Triphosphate Prodrugs of Anti-HIV Active Nucleoside Analogs as Potential Antiviral Compounds Only after all three phosphate groups are attached can the analog compete with natural nucleotides for a spot in a growing strand of DNA or RNA.
This activation process depends on enzymes called kinases, some of which belong to the host cell and some of which are encoded by the virus itself.4PubMed. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties That distinction turns out to be crucial for drug selectivity, as we will see with herpes drugs like acyclovir. The first phosphorylation step is often the bottleneck. If a cell lacks the right kinase to perform that initial step, the analog stays inert. Enzymes called nucleoside monophosphate kinases handle the second step, and they are needed for both natural nucleosides and their analogs.5PubMed. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases
How They Wreck the Copying Machine
Once an analog is fully phosphorylated, it competes with the natural nucleotide for incorporation into a growing DNA or RNA chain. What happens next depends on the specific analog’s design. There are several distinct strategies, and understanding the differences explains why different drugs are suited to different diseases.
The classic approach is called obligate chain termination. The drug zidovudine (AZT), the first approved treatment for HIV, works this way. AZT lacks a key chemical group on its sugar that the polymerase enzyme needs in order to attach the next nucleotide in the chain. Once AZT is incorporated, the chain simply cannot grow any further, and viral DNA synthesis grinds to a halt.6PubMed. Antimicrobial strategies: inhibition of viral polymerases by 3′-hydroxyl nucleosides
Not all analogs work so abruptly. Some allow the polymerase to add a few more nucleotides before stalling. Remdesivir, developed initially against Ebola and later used against coronaviruses, is a delayed chain terminator. After remdesivir is incorporated, the polymerase manages to add about three more nucleotides before hitting a wall.7Journal of Biological Chemistry. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus This delay can make it harder for the virus’s error-checking machinery to detect and remove the fake nucleotide.
A third, more radical strategy is lethal mutagenesis. Instead of stopping the chain, the analog gets incorporated and then causes the polymerase to make catastrophic errors when copying the strand that contains it. Molnupiravir, used against SARS-CoV-2, works this way. Its active form can pair with two different bases depending on its shape at any given moment, which floods the viral genome with mutations until the virus can no longer produce functional proteins.8Molecular Therapy Nucleic Acids. Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus
Antiviral Workhorses
Nucleoside analogs have been central to antiviral medicine for decades. The HIV story is probably the most consequential. After AZT’s approval in 1987, a whole class of drugs called nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) emerged. These drugs target the enzyme HIV uses to convert its RNA genome into DNA. NRTIs became the backbone of combination antiretroviral therapy and remain so today, used not only for treatment but also for preventing mother-to-child transmission and as pre-exposure prophylaxis for people at risk of infection.9PubMed Central. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection10PubMed. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Acyclovir, used against herpes simplex and varicella-zoster viruses, illustrates how an analog can be remarkably selective. Acyclovir is barely activated in healthy cells because human enzymes do not efficiently phosphorylate it. But herpes viruses encode their own thymidine kinase, an enzyme with unusually broad taste in what it will phosphorylate, and this viral enzyme readily performs the first activation step.11PubMed. Mechanism of action and selectivity of acyclovir The herpes thymidine kinase accepts acyclovir’s unusual acyclic sugar structure, while the human version of the enzyme does not, which is why acyclovir has relatively few side effects compared to many other antivirals.12Journal of Biological Chemistry. Substrate Diversity of Herpes Simplex Virus Thymidine Kinase
Hepatitis C treatment was transformed by sofosbuvir, a nucleotide analog that targets the viral RNA polymerase. Once activated, sofosbuvir’s triphosphate form gets incorporated into the growing RNA chain and acts as a chain terminator, halting viral replication.13PubMed Central. Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs Sofosbuvir-based regimens turned hepatitis C from a chronic, liver-destroying infection into a disease curable in most patients within a few months.14PubMed Central. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
Fighting Cancer With the Same Trick
The logic that works against viruses also works against rapidly dividing cancer cells. If you can slip a defective building block into DNA during replication, you can stall or kill cells that are copying their genomes at a frantic pace. Two of the most important cancer-fighting nucleoside analogs are cytarabine (ara-C) and gemcitabine, both modified versions of the natural nucleoside cytidine.
Cytarabine and gemcitabine both carry modifications on their sugar ring that allow them to be incorporated into DNA but then interfere with the next round of synthesis. Cytarabine has an extra hydroxyl group that locks the sugar into a shape unfavorable for continued DNA extension, while gemcitabine has two fluorine atoms that alter the sugar ring’s ability to shift into the right configuration for the next step.15PubMed Central. Sugar ring alignment and dynamics underline cytarabine and gemcitabine inhibition on Pol η catalyzed DNA synthesis Both end up blocking DNA replication after being incorporated.16Biochemistry. Incorporation of Gemcitabine and Cytarabine into DNA by DNA Polymerase β and Ligase III/XRCC1 Cytarabine has been a mainstay of leukemia treatment for decades, while gemcitabine is used against pancreatic, lung, bladder, and breast cancers.
Some nucleoside analogs fight cancer through an entirely different mechanism. Azacytidine and its close relative decitabine do not primarily work by stopping DNA replication. Instead, once incorporated into DNA, they trap and deplete enzymes called DNA methyltransferases that are responsible for adding chemical tags to genes. In cancer, abnormal methylation patterns can silence tumor-suppressor genes, and by stripping away those tags, azacytidine can reactivate genes that keep cell growth in check.17PubMed. Azacytidine causes complex DNA methylation responses in myeloid leukemia In clinical studies, azacytidine treatment reduced methylation levels in patient samples, with the effect peaking during treatment and then partially rebounding afterward.18PubMed Central. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers
Why They Can Hurt Healthy Cells Too
The fundamental limitation of nucleoside analogs is that healthy cells also replicate DNA. Any cell that is actively dividing, whether in the bone marrow, the gut lining, or the immune system, can be caught in the crossfire. This is why common side effects of these drugs include low blood counts, nausea, and immune suppression.
For antiviral nucleoside analogs used in HIV treatment, there is a more specific concern. Human cells contain a separate DNA polymerase inside their mitochondria, the energy-producing compartments of the cell. This mitochondrial polymerase can be inhibited by NRTIs, leading to a form of toxicity that damages mitochondrial function.19PubMed Central. Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ Symptoms of mitochondrial toxicity range from muscle weakness and nerve damage to a dangerous buildup of lactic acid. Different NRTIs vary in how strongly they inhibit this enzyme, and drug design over the years has aimed to minimize this off-target effect. Newer NRTIs are considerably better tolerated than the earliest ones.
How Pathogens Fight Back
Viruses and cancer cells can evolve resistance to nucleoside analogs, and they use several strategies to do so. In HIV, mutations in the reverse transcriptase enzyme can either prevent the analog from being incorporated or enable the enzyme to remove the analog after it has been inserted, allowing the chain to resume growing. This is one reason HIV is treated with combinations of drugs rather than a single agent.9PubMed Central. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection
Coronaviruses pose a particularly interesting resistance challenge. They carry a built-in proofreading enzyme, an exonuclease that can detect and snip out mismatched or abnormal nucleotides from a newly synthesized RNA strand. This proofreading ability complicates treatment with nucleoside analogs because the virus can sometimes remove the drug before it does lasting damage. Studies with remdesivir showed that coronaviruses lacking this proofreading enzyme were significantly more sensitive to the drug, and that mutations in the polymerase itself could confer up to roughly six-fold resistance.20PubMed Central. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Cancer cells develop resistance through a different set of tricks. Because analogs must be phosphorylated inside the cell, cancer cells can reduce the levels of the kinase enzyme responsible for the first activation step, starving the drug of the processing it needs. They can also ramp up enzymes that dephosphorylate the analog, effectively deactivating it. In laboratory studies of leukemia cell lines resistant to several nucleoside analogs, this dephosphorylating enzyme activity was strongly increased, while the activating kinase was reduced, resulting in lower levels of the active drug form inside the cell.21PubMed. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
Getting Drugs Where They Need to Go
Many nucleoside analogs are polar molecules, meaning they do not easily cross fatty cell membranes or barriers like the blood-brain barrier. This creates a practical problem: even if a drug is potent against a virus in a test tube, it may not reach the right tissues in sufficient concentrations. Early studies of the HIV drug didanosine (ddI) found that its concentration in cerebrospinal fluid was less than 2% of what was found in the blood, a major limitation for treating HIV infection in the brain.22Journal of Controlled Release. Approaches toward the optimization of CNS uptake of anti-AIDS agents
Research into nucleoside transporters, the proteins that ferry nucleosides across cell membranes, has revealed another complication. Many antiviral nucleoside analogs lack a specific hydroxyl group on the sugar that these transporters use to recognize their cargo, meaning the analogs cannot hitch a ride into cells the way natural nucleosides do.23Journal of Drug Targeting. Interaction of Nucleoside Analogues with Nucleoside Transporters in Rat Brain Endothelial Cells
One elegant solution to these delivery problems is the ProTide approach, a prodrug technology that masks the phosphate group of the analog with small chemical attachments that make the molecule more able to cross cell membranes. Once inside the cell, enzymes strip away the mask, releasing the active monophosphate form and bypassing the often-inefficient first phosphorylation step entirely.24PubMed Central. The ProTide Prodrug Technology: From the Concept to the Clinic Sofosbuvir and the active form of remdesivir (GS-5734) both use ProTide chemistry, and it is part of what made them clinically successful.
Modified Nucleosides in mRNA Vaccines
The concept of tweaking nucleosides extends beyond drugs that kill viruses or cancer cells. The mRNA vaccines developed against COVID-19 rely on a modified nucleoside called N1-methylpseudouridine to make the synthetic mRNA work inside human cells.25PubMed Central. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines Natural mRNA injected into the body triggers a strong immune alarm that destroys the message before cells can read it. By replacing one of the standard RNA building blocks with N1-methylpseudouridine, researchers found they could dramatically reduce this immune reaction while increasing how much protein the mRNA instructed cells to produce. In cell and animal experiments, mRNA made with this modification produced up to roughly 13-fold more protein than mRNA made with an earlier modified nucleoside, pseudouridine.26PubMed. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
This is not a drug designed to kill anything. It is the same underlying insight, that small chemical changes to a nucleoside can profoundly alter how biological machinery handles it, applied in a completely different direction. The modification makes the mRNA invisible to the cell’s innate immune sensors while keeping it readable by the cell’s protein-making machinery. Without this trick, the mRNA vaccine platform would likely not have been practical for widespread use.
Expanding the Genetic Alphabet
Researchers have pushed the nucleoside-analog concept even further, creating entirely synthetic nucleosides that do not correspond to any of the four natural bases. These “unnatural base pairs” can be incorporated into DNA alongside the natural A-T and G-C pairs, effectively expanding the genetic alphabet from four letters to six.27PubMed Central. Unnatural base pair systems toward the expansion of the genetic alphabet in the central dogma Synthetic DNA containing these extra letters can be faithfully copied by PCR and transcribed into RNA.
After more than 20 years of development, researchers created semi-synthetic organisms, bacteria that stably maintain an unnatural base pair in their DNA, transcribe it, and even use it to produce proteins containing unnatural amino acids.28PubMed Central. Discovery, implications and initial use of semi-synthetic organisms with an expanded genetic alphabet/code The immediate applications are in biotechnology rather than medicine: an expanded genetic code could allow the production of proteins with properties impossible to achieve using only the 20 standard amino acids. But the work grows from the same root as antiviral and anticancer drug design. Understanding how polymerases interact with nucleosides, what they accept, and what they reject has opened the door not just to drugs that exploit the copying machinery but to an expansion of the machinery itself.29PubMed Central. Discovery, characterization, and optimization of an unnatural base pair for expansion of the genetic alphabet